Concord Biotech Ltd (CONB)

Currency in INR
1,327.20
+159.00(+13.61%)
Closed·
Unusual trading volume
Earnings results expected in 0 days
CONB is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
1,144.101,385.00
52 wk Range
1,100.002,451.70
Key Statistics
Bid/Ask
1,327.20 / 1,327.20
Prev. Close
1,168.2
Open
1,164.8
Day's Range
1,144.1-1,385
52 wk Range
1,100-2,451.7
Volume
3.83M
Average Volume (3m)
144.63K
1-Year Change
-43.4175%
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
CONB Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
1,545.83
Upside
+16.47%
Members' Sentiments
Bearish
Bullish
ProTips
Prominent player in the Pharmaceuticals industry

Concord Biotech Ltd News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Strong Buy

Concord Biotech Company Profile

Concord Biotech Limited, a biopharma company, engages in the research and development, manufacture, market, and sale of pharmaceutical products in India and internationally. The company provides fermentation based active pharmaceutical ingredients in immunosuppressants, anti-bacterial, oncology, antifungal, and other therapeutic areas. It also offers tacrolimus, mycophenolate mofetil, mycophenolate sodium, cyclosporine, sirolimus, voclosporin, and pimecrolimus for immunosuppressants therapeutic segment; and temsirolimus, everolimus, romidepsin, doxorubicin, mitomycin, midostaurin, and dactinomycin for oncology therapeutic segment. In addition, the company provides mupirocin, mupirocin calcium, polymyxin B sulfate, fidaxomicin, vancomycin hydrochloride, and teicoplanin for anti-bacterial applications; anidulafungin, caspofungi, micafungin sodium, and nystatin for anti-fungal therapeutic segment; and lovastatin and pravastatin sodium for other applications. Further, it develops daptomycin for anti-infectives applications; and epirubicin, idarubicin, and pirarubicin for oncology therapeutic segment. Additionally, the company provides contract research and manufacturing services in the areas of fermentation and semi-synthesis products. Concord Biotech Limited was incorporated in 1984 and is based in Ahmedabad, India.

Employees
1571
Market
India

Compare CONB to Peers and Sector

Metrics to compare
CONB
Peers
Sector
Relationship
P/E Ratio
42.9x28.5x−0.5x
PEG Ratio
−29.070.350.00
Price/Book
7.6x5.0x2.6x
Price / LTM Sales
12.3x3.8x3.3x
Upside (Analyst Target)
19.4%13.6%45.8%
Fair Value Upside
Unlock9.4%6.4%Unlock

Analyst Ratings

4 Buy
2 Hold
0 Sell
Ratings:
6 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 1,545.83
(+16.47% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
Jefferies
Hold1,290.00-2.80%1,500.00Maintain09/01/2026
Kotak
Buy1,560.00+17.54%-Maintain10/12/2025
Citi
Hold1,680.00+26.58%1,880.00Maintain27/10/2025
Kotak
Buy1,825.00+37.51%-Maintain29/09/2025
Kotak
Buy1,825.00+37.51%1,875.00Maintain12/08/2025

Dividends

Payout Ratio
Payout ratio (TTM)
Earnings retained
EPS 30.89%
Dividend Yield
0.81%
Industry Median 0.78%
Annualised payout
10.70
Paid annually
5-Years Growth
-
Growth Streak

Earnings

Latest Release
Nov 13, 2025
EPS / Forecast
6.10 / 4.80
Revenue / Forecast
2.47B / 2.73B
EPS Revisions
Last 90 days

People Also Watch

3,700.30
KAYN
+2.33%
967.70
KFIN
-2.49%
268.10
JIOF
-0.69%
784.70
HBLO
+0.66%
617.65
TATE
-3.91%

FAQ

What Is the Concord Biotech (CONB) Share Price Today?

The live Concord Biotech share price today is 1,327.20

What Stock Exchange Does Concord Biotech (CONB) Trade On?

Concord Biotech is listed and trades on the India National Stock Exchange.

What Is the Ticker (Stock Symbol) for Concord Biotech?

The stock symbol (also called a 'ticker') for Concord Biotech is "CONB."

Does Concord Biotech Pay Dividends? What’s The Current CONB Dividend Yield?

Yes, CONB Pays Dividends to its Shareholders. The current Concord Biotech dividend yield is 0.81%.

What Is the Current Concord Biotech Market Cap?

As of today, Concord Biotech market capitalisation is 138.85B.

What Is Concord Biotech's (CONB) Earnings Per Share (TTM)?

The Concord Biotech EPS is currently 30.89 (Trailing Twelve Months).

When Is the Next Concord Biotech Earnings Date?

Concord Biotech's next earnings report will be released on 11 Feb 2026.

Is CONB a Buy or Sell From a Technical Analyst Perspective?

Based on today's Concord Biotech moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.

How Many Times Has Concord Biotech Stock Split?

Concord Biotech has split 0 times. (See the CONB stock split history page for full effective split date and price information.)

How Many Employees Does Concord Biotech Have?

Concord Biotech has 1571 employees.

What is the current trading status of Concord Biotech (CONB)?

As of 08 Feb 2026, Concord Biotech (CONB) is trading at a price of 1,327.20, with a previous close of 1,168.20. The stock has fluctuated within a day range of 1,144.10 to 1,385.00, while its 52-week range spans from 1,100.00 to 2,451.70.

What Is Concord Biotech (CONB) Price Target According to Analysts?

The average 12-month price target for Concord Biotech is INR1,545.83, with a high estimate of INR1680 and a low estimate of INR1290. 4 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Buy. The stock has an +16.47% Upside potential.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.